This trial is testing a new combination of drugs for relapsed or refractory AML patients. The first part of the trial will determine the maximum tolerated dose of the new drugs. The second part will expand the trial to more patients using the maximum tolerated dose.
1 Primary · 1 Secondary · Reporting Duration: 7 years
Experimental Treatment
22 Total Participants · 3 Treatment Groups
Primary Treatment: CC-486 · No Placebo Group · Phase 1
Age 18 - 100 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: